BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

Impact · against what's priced in

Amicus Therapeutics shareholders receive a significant liquidity event via an all-cash acquisition at a premium. For BioMarin, the deal provides immediate revenue diversification and earnings accretion through the addition of Galafold and Pombiliti + Opfolda.

FOLD+0.90

No priced-in read yet